ARTHEx Biotech S.L. will participate in the 8th Annual Chardan Genetic Medicines Conference, scheduled for September 30 - October 1, 2024, in New York, NY. The company is focused on advancing innovative medicines through gene expression modulation.
Frédéric Legros, Executive Chairman and CEO of ARTHEx Biotech, will be available for one-on-one meetings with investors throughout the conference. This engagement provides an opportunity to discuss the company's progress and strategic direction in developing treatments for genetically-driven diseases.
ATX-01 for Myotonic Dystrophy Type 1 (DM1)
ARTHEx Biotech's lead investigational compound, ATX-01, is currently undergoing evaluation in the Phase I-IIa ArthemiR™ trial for the treatment of myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder. DM1 is characterized by progressive muscle weakness and affects multiple organ systems, representing a significant unmet medical need.
Advancing microRNA Modulators
In addition to ATX-01, ARTHEx Biotech is leveraging its in-house discovery engine to identify and develop microRNA modulators for other disorders with high unmet medical needs, including genetically-driven diseases like DM1. MicroRNAs play a crucial role in gene regulation, and modulating their activity holds promise for therapeutic intervention in various diseases.
